Abstract：
The oligometastatic state in non-small cell lung cancer (NSCLC) has recently become well-established. However, the specific definition of oligometastases remains unclear. Several smaller randomized studies have investigated the safety and efficacy of radiation as metastasis-directed therapy (MDT) in oligometastatic NSCLC, which have led the way to larger studies currently accruing patients globally.
This review covers the definitions of \'oligometastases\' and explains why the oligometastatic state is becoming increasingly relevant in metastatic NSCLC. This includes the rationale for MDT in oligometastatic NSCLC, specifically reviewing stereotactic body radiation therapy (SBRT) as a treatment strategy. This review details many randomized trials that support radiation as MDT and introduces trials that are currently accruing patients. Finally, it explores some of the controversies that warrant further investigation.
Radiation treatment, specifically SBRT, has been shown to be safe, convenient, and cost-effective as MDT. As systemic therapy, including targeted agents and immunotherapy, continues to improve, the precise role(s) and timing of radiation therapy may evolve. However, radiation therapy as MDT will continue to be an integral part of treatment in patients with oligometastatic NSCLC.
This review covers the definitions of \'oligometastases\' and explains why the oligometastatic state is becoming increasingly relevant in metastatic NSCLC. This includes the rationale for MDT in oligometastatic NSCLC, specifically reviewing stereotactic body radiation therapy (SBRT) as a treatment strategy. This review details many randomized trials that support radiation as MDT and introduces trials that are currently accruing patients. Finally, it explores some of the controversies that warrant further investigation.
Radiation treatment, specifically SBRT, has been shown to be safe, convenient, and cost-effective as MDT. As systemic therapy, including targeted agents and immunotherapy, continues to improve, the precise role(s) and timing of radiation therapy may evolve. However, radiation therapy as MDT will continue to be an integral part of treatment in patients with oligometastatic NSCLC.
摘要：
■非小细胞肺癌（NSCLC）的寡转移状态最近已得到确认。然而,寡转移酶的具体定义尚不清楚.一些较小的随机研究已经调查了放射作为转移定向治疗（MDT）在寡转移性NSCLC中的安全性和有效性。这导致了目前在全球范围内积累患者的更大研究。
■这篇综述涵盖了“寡转移酶”的定义，并解释了为什么寡转移状态在转移性NSCLC中变得越来越重要。它包括MDT在寡转移性NSCLC中的基本原理，特别回顾立体定向身体放射治疗（SBRT）作为治疗策略。这篇综述详细介绍了许多支持放射作为MDT的随机试验，并介绍了目前正在增加患者的试验。最后,它探讨了一些需要进一步调查的争议。
■放射治疗，特别是SBRT，已经证明是安全的，方便,和MDT一样具有成本效益。作为全身治疗，包括靶向药物和免疫疗法，继续改善,放射治疗的确切作用和时机可能会演变。然而,作为MDT的放射治疗将继续成为寡转移性NSCLC患者治疗的一个组成部分.
■这篇综述涵盖了“寡转移酶”的定义，并解释了为什么寡转移状态在转移性NSCLC中变得越来越重要。它包括MDT在寡转移性NSCLC中的基本原理，特别回顾立体定向身体放射治疗（SBRT）作为治疗策略。这篇综述详细介绍了许多支持放射作为MDT的随机试验，并介绍了目前正在增加患者的试验。最后,它探讨了一些需要进一步调查的争议。
■放射治疗，特别是SBRT，已经证明是安全的，方便,和MDT一样具有成本效益。作为全身治疗，包括靶向药物和免疫疗法，继续改善,放射治疗的确切作用和时机可能会演变。然而,作为MDT的放射治疗将继续成为寡转移性NSCLC患者治疗的一个组成部分.
